Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Industry

News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Build up of toxic DNA may drive geographic atrophy

Researchers are exploring the potential of treating age-related macular degeneration with common HIV drugs

NDA
A new study published in Science Advances has highlighted the potential for common HIV drugs to be used in the treatment of geographic atrophy.

Researchers described how harmful DNA, called Alu cDNA, accumulates at the leading edge of geographic atrophy lesions. The DNA triggers inflammation that leads to the death of retinal cells.

Scientists are exploring the potential of HIV medication, nucleoside reverse transcriptase inhibitors (NRTIs), that block inflammation and could protect against retinal cell death.

Previous research that examined data from more than 100 million patients over two decades across four different health insurance data bases found that people taking NRTIs were almost 40% less likely to develop dry age-related macular degeneration.

Dr Jayakrishna Ambati, of the University of Virginia School of Medicine, highlighted that the findings provide support for conducting clinical trials testing NRTIs or safer derivatives, kamuvudines, in patients with macular degeneration.

"We are very hopeful that a clinical trial of kamuvudines will be launched soon in geographic atrophy so that we can potentially offer a treatment for this devastating condition,” Ambati said.

Advertisement